Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
نویسندگان
چکیده
منابع مشابه
Significance of Wilms’ Tumor Gene 1 as a Biomarker in Acute Leukemia and Solid Tumors
Wilms’ tumor gene 1 (WT1) is a zinc finger transcriptional regulator with crucial functions in embryonic development. Originally WT1 was described as a tumor suppressor gene, but later studies have shown oncogenic properties of WT1 in a variety of tumors. Because of its dual functions in tumorigenesis, WT1 has been described as a chameleon gene. In this thesis, the significance of WT1 as a biom...
متن کاملCirculating giant macrophages as a potential biomarker of solid tumors.
Tumor-associated macrophages (TAMs) derived from primary tumors are believed to facilitate circulating tumor cell (CTC) seeding of distant metastases, but the mechanisms of these processes are poorly understood. Although many studies have focused on the migration of CTCs, less attention has been given to TAMs that, like CTCs, derive from tumor sites. Using precision microfilters under low-flow ...
متن کاملGlycine as a biomarker in brain tumors
Introduction− Glycine is a major inhibitory neurotransmitter in the mammalian central nervous system [1]. High levels of glycine have been detected in the brain of patients with hyperglycinemia and in brain tumors in particular glioblastoma multiforme (GBM) [2-4]. Given its significance, an accurate measure of brain glycine is desirable; this is hindered by the fact that its resonance overlaps ...
متن کاملPseudocholinesterase activity in cerebrospinal fluid as a biomarker of solid central nervous system tumors in children
AIM To determine the activity of pseudocholinesterase (PChE) in cerebrospinal fluid (CSF) and serum in children with solid central nervous system (CNS) tumor and to assess whether PChE activity could be a valid biomarker for solid CNS tumors in children. METHODS The study and control group included 30 children each. Children in the study group had a solid CNS tumor, while those from the contr...
متن کاملDiastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.
PURPOSE To evaluate if diastolic blood pressure (dBP) ≥90 mm Hg during axitinib treatment is a marker of efficacy. EXPERIMENTAL DESIGN The relationship between dBP ≥90 mm Hg and efficacy was retrospectively explored across 5 phase II studies of single-agent axitinib for the treatment of 4 different tumor types. All patients had baseline BP ≤140/90 mm Hg and were stratified into 2 groups based...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Discovery
سال: 2020
ISSN: 2159-8274,2159-8290
DOI: 10.1158/2159-8290.cd-20-0522